BeyondSpring Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BeyondSpring stock.
View analyst ratings for BeyondSpring or view top-rated stocks.

Wall Street analysts have given BeyondSpring a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BeyondSpring wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

BeyondSpring saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,150,000 shares, an increase of 16.5% from the December 31st total of 987,500 shares. Based on an average daily trading volume, of 462,500 shares, the days-to-cover ratio is presently 2.5 days. Approximately 5.5% of the company's stock are sold short.
View BeyondSpring's Short Interest.

BeyondSpring is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for BeyondSpring.

BeyondSpring Inc. (NASDAQ:BYSI) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.06.
View BeyondSpring's earnings history.

BeyondSpring's stock was trading at $11.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BYSI stock has increased by 20.9% and is now trading at $13.72.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 12-month target prices for BeyondSpring's stock. Their forecasts range from $25.00 to $43.00. On average, they expect BeyondSpring's share price to reach $32.67 in the next year. This suggests a possible upside of 138.1% from the stock's current price.
View analysts' price targets for BeyondSpring or view top-rated stocks among Wall Street analysts.

Some companies that are related to BeyondSpring include Harmony Biosciences (HRMY), Generation Bio (GBIO), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Stoke Therapeutics (STOK), Myovant Sciences (MYOV), ADC Therapeutics (ADCT), NGM Biopharmaceuticals (NGM), Praxis Precision Medicines (PRAX), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Seres Therapeutics (MCRB), COMPASS Pathways (CMPS) and ImmunoGen (IMGN).
View all of BYSI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

BeyondSpring's stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (7.04%), BlackRock Inc. (3.04%), Northern Trust Corp (0.64%), Nuveen Asset Management LLC (0.31%), Renaissance Technologies LLC (0.32%) and Blair William & Co. IL (0.24%).

BYSI stock was sold by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, and Barclays PLC.

BYSI stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., BlackRock Inc., Nuveen Asset Management LLC, Endurance Wealth Management Inc., Renaissance Technologies LLC, Laurion Capital Management LP, Blair William & Co. IL, and JPMorgan Chase & Co..

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BYSI stock can currently be purchased for approximately $13.72.

BeyondSpring has a market capitalization of $537.03 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

BeyondSpring employs 61 workers across the globe.

The official website for BeyondSpring is www.beyondspringpharma.com.

BeyondSpring is headquartered at 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005.

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]